This collaboration aims to streamline the process of capturing cognitive function and eCOA/ePRO data, marking a significant milestone in the field of neurological research.
In announcing the partnership with MoCA Cognition, uMotif CEO Steve Rosenberg explained: “The goal is to bring sponsors, CROs, sites and patients the combined power of modern eCOA/ePRO and groundbreaking cognitive tools that deliver a quantifiable improvement in patient engagement and data quality in the vital area of CNS research.”
The collaboration between uMotif and MoCA Cognition signifies a deepening commitment to CNS research, with a focus on exploring the therapeutic potential of psychedelics in treating conditions such as schizophrenia and major depressive disorder.
Dr. Ziad Nasreddine, CEO of MoCA Cognition and the visionary behind the MoCA Test, underscored the importance of delivering a patient-centric approach to cognitive assessment. With the MoCA Test available in over 200 languages and dialects, and now offered in digital formats for enhanced accessibility, the partnership aims to empower clinicians and researchers worldwide in their efforts to detect cognitive impairment swiftly and accurately.
Nasreddine said: “Many of us see how brain diseases affect people in our own lives. Delivering a patient-centric approach to capturing cognitive function and other outcome measures has many use cases. It can help day-to-day healthcare, as well as provide a unique approach to clinical trial recruitment, screening, and data capture. We look forward to working with uMotif to explore the XpressO application for clinical trials.”
The introduction of MoCA’s new XpressO test represents a significant advancement in cognitive pre-screening. This self-administered digital tool offers sponsors and CROs a sophisticated approach to differentiating between subjective and objective cognitive impairment, thus facilitating rapid and scalable study pre-screening.
By integrating the standard MoCA test and XpressO into the uMotif platform, researchers can now capture a comprehensive set of eCOA/ePRO data alongside cognitive assessments, significantly reducing screen fail rates and accelerating study timelines. Validation studies have demonstrated the efficacy of XpressO in comparison to the digital MoCA test, further cementing its credibility as a valuable tool in CNS research.
Notably, solutions utilizing the standard MoCA test and the uMotif platform are available for immediate deployment, signaling a readiness to implement this integrated approach in ongoing and future research initiatives.
This collaboration follows uMotif’s recent partnership with cognitive science leaders Cogstate Ltd, further solidifying its commitment to advancing CNS research. By leveraging the combined expertise of uMotif and Cogstate, researchers can access a comprehensive suite of digital assessment tools and support services, bolstering the efficiency and efficacy of clinical trials in the CNS space.
As the landscape of CNS research continues to evolve, the partnership between uMotif and MoCA Cognition stands poised to drive meaningful advancements in understanding and treatment of neurological disorders, ultimately improving the lives of patients worldwide.
